Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23627579 | 0.94 | TSHR (0.50) | TSHRALDH1A1GAASMN1; SMN2CYP2C19 | |
| SCHEMBL7639964 | 0.90 | FKBP1A (0.50) | TSHRALDH1A1GAASMN1; SMN2CYP2C19 | |
| SCHEMBL304689 | 0.87 | FKBP1A (0.53) | TSHRALDH1A1GAASMN1; SMN2CYP2C19 | |
| SCHEMBL7642406 | 0.87 | ALDH1A1 (0.55) | TSHRALDH1A1GAASMN1; SMN2CYP2C19 | |
| SCHEMBL20625314 | 0.86 | TSHR (0.50) | TSHRALDH1A1GAATRPM8SMN1; SMN2 | |
| SCHEMBL7641957 | 0.86 | ALDH1A1 (0.53) | ALDH1A1GAASMN1; SMN2CYP2C19FKBP1A | |
| SCHEMBL2706422 | 0.86 | ALDH1A1 (0.53) | ALDH1A1GAASMN1; SMN2CYP2C19FKBP1A | |
| SCHEMBL7637109 | 0.86 | ALDH1A1 (0.53) | ALDH1A1GAASMN1; SMN2CYP2C19FKBP1A | |
| SCHEMBL22644548 | 0.80 | ALDH1A1 (0.49) | TSHRALDH1A1GAASMN1; SMN2CYP2C19 | |
| SCHEMBL23306961 | 0.80 | ALDH1A1 (0.49) | TSHRALDH1A1GAASMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954266-B2 | Linker molecule and use thereof in methods for purifying peptides | Belyntic GmbH (DE) | 2021-03-23 | — | — | US | disclosed |
| US-20190309013-A1 | LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES | Belyntic GmbH (DE) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190309013-A1 | LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES | SPPL2B, VIP, SPPL2A | TSHR 2400/4885ALDH1A1 3986/4885GAA 3313/4885 |
| US-10954266-B2 | Linker molecule and use thereof in methods for purifying peptides | SPPL2B, VIP, SPPL2A | TSHR 2400/4885ALDH1A1 3986/4885GAA 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.